Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Ramantamig |
| Trade Name | |
| Synonyms | JNJ 79635322|JNJ79635322|JNJ-79635322 |
| Drug Descriptions |
Ramantamig (JNJ-79635322) is a trispecific antibody that targets TNFRSF17 (BCMA) and GPRC5D on tumor cells, and CD3 on T-cells, which potentially induces cytotoxicity against tumor cells (PMID: 41100731). |
| DrugClasses | CD3 Antibody 119 TNFRSF17 Antibody 22 |
| CAS Registry Number | 2988886-91-3 |
| NCIT ID | C216004 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Daratumumab + Lenalidomide + Ramantamig | Daratumumab Lenalidomide Ramantamig | 0 | 1 |
| Daratumumab + Ramantamig | Daratumumab Ramantamig | 0 | 1 |
| Pomalidomide + Ramantamig | Pomalidomide Ramantamig | 0 | 1 |
| Ramantamig | Ramantamig | 0 | 1 |